This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight

Q: What is the NCT07017179 clinical trial studying?

This study is to assess the safety and tolerability, PK characterisation, efficacy, and immunogenicity of the study intervention, and it allows assessment of the monotherapy or combination therapy of AZD6234 and AZD9550 in different sub-studies. The full protocol is registered on ClinicalTrials.gov and includes the primary outcome measures, eligibility criteria, and study endpoints.

Q: Who can participate in NCT07017179?

Eligibility for this trial depends on the specific inclusion and exclusion criteria set by the sponsor. The plain-English summary above translates the most important criteria into accessible language; the official clinical text is preserved in the collapsible section underneath. Whether you fit any specific trial is a medical decision your doctor needs to confirm — bring the trial information to your treating physician for a full review against your medical history.

Q: How do I contact the trial site for NCT07017179?

Contact information registered with ClinicalTrials.gov is shown in the sidebar of this page. Before reaching out, confirm with your treating physician that this trial is appropriate for your situation. The trial site will then walk you through the screening process to determine final eligibility.

Q: Is participating in a clinical trial safe?

Clinical trials in the United States are regulated by the FDA and overseen by Institutional Review Boards (IRBs) that review the protocol for safety. Risk varies by trial — Phase 1 studies test new treatments in humans for the first time, while Phase 3 trials use treatments that have already passed earlier safety screening. The informed consent document for any specific trial details the known risks and what to expect. Discuss those risks with your physician before deciding whether to participate.

Q: Where can I verify the data on this page?

Every detail on this page comes directly from the ClinicalTrials.gov API. Click "View on ClinicalTrials.gov" in the sidebar to see the official, unmodified record. The federal record is always authoritative; this page is a structured presentation with a plain-English eligibility translation. For background on how clinical trials are regulated, see the FDA drug approval process documentation.

A Phase IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD6234, AZD9550, and AZD6234 in Combination With AZD9550 in Chinese Participants Living With Obesity/Overweight

This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight (NCT07017179) is a Phase 2 interventional studying Obesity/Overweight, sponsored by AstraZeneca. RECRUITING as of the most recent ClinicalTrials.gov update. Talk to your doctor before contacting the trial site.

About This Trial

What Stage of Research Is This?

Phase 2 trials evaluate whether a treatment actually works against Obesity/Overweight and continue monitoring side effects. Phase 2 enrolls larger groups (typically 100–300 patients) and produces the first real efficacy signal. A successful Phase 2 readout is what unlocks the much larger Phase 3 confirmatory trials needed for FDA approval.

This trial is currently recruiting participants. The sponsor has registered the study with ClinicalTrials.gov as actively enrolling, which means new applicants who meet the eligibility criteria can be considered for screening. Trial status can change between updates — confirm current recruiting status with the study contact before traveling for a screening visit.

A target enrollment of 871 participants makes this a sizable late-stage trial. Studies in this range typically have enough power to detect clinically meaningful differences from a comparator and to characterize less-common side effects.

Who May Be Eligible (Plain English)

Who May Qualify: 1. Age 18 to 55 years. 2. BMI ≥ 27 kg/m2. 3. Stable body weight for 3 months prior to screening. 4. Male and female (Contraceptive use by participants or participant partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies). 5. Participants should refrain from blodd donation throughout the sub-study, including the follow-up period. 6. Negative pregnancy test at screening and randomisation for FOCBP and must not be breastfeeding. Who Should NOT Join This Trial: 1. Have received prescription medication or non-prescription medication for weight loss within the last 3 months prior to screening. 2. History of type 1 or type 2 diabetes mellitus or symptoms indicative of insulinopenia or poor glucose control. 3. Treatment with diabetes medication in past 3 months prior to screening. 4. HbA1c ≥ 6.5% (48 mmol/mol) at screening. 5. Gastroparesis (or similar) requiring treatment. 6. Significant inflammatory bowel disease or other severe disease or surgery affecting the upper GI tract. 7. Significant hepatic disease (except for non-alcoholic steatohepatitis or non-alcoholic fatty liver disease without portal hypertension or cirrhosis) and/or participants with any of the following results at screening: 1. AST ≥ 2.5 × ULN 2. ALT ≥ 2.5 × ULN 3. TBL ≥ 1.5 × ULN. 8. Prior history of cholecystectomy or untreated cholelithiasis. 9. History of acute or chronic pancreatitis or pancreatic amylase or lipase \> 2 × ULN at screening. 10. Severely uncontrolled hypertension defined as systolic BP ≥ 160 mmHg and/or diastolic BP ≥ 100 mmHg on the average of 2 seated measurements after being at rest for at least 5 minutes. 11. HR \< 50 bpm or \> 100 bpm after being at rest for 5 minutes. 12. Impaired renal function defined as eGFR ≤ 45 mL/minute/1.73 m2 at screening (GFR estimated according to CKD-EPI). 13. History of psychosis or bipolar disorder. ...See full criteria on ClinicalTrials.gov Always talk to your doctor about whether this trial is right for you.

These are translations of the protocol\'s inclusion and exclusion criteria, simplified for patients and caregivers. The original clinical text appears below. Eligibility is ultimately confirmed by the trial site\'s screening process — this summary is a starting point for a conversation with your doctor, not a final determination.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: 1. Age 18 to 55 years. 2. BMI ≥ 27 kg/m2. 3. Stable body weight for 3 months prior to screening. 4. Male and female (Contraceptive use by participants or participant partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies). 5. Participants should refrain from blodd donation throughout the sub-study, including the follow-up period. 6. Negative pregnancy test at screening and randomisation for FOCBP and must not be breastfeeding. Exclusion Criteria: 1. Have received prescription medication or non-prescription medication for weight loss within the last 3 months prior to screening. 2. History of type 1 or type 2 diabetes mellitus or symptoms indicative of insulinopenia or poor glucose control. 3. Treatment with diabetes medication in past 3 months prior to screening. 4. HbA1c ≥ 6.5% (48 mmol/mol) at screening. 5. Gastroparesis (or similar) requiring treatment. 6. Significant inflammatory bowel disease or other severe disease or surgery affecting the upper GI tract. 7. Significant hepatic disease (except for non-alcoholic steatohepatitis or non-alcoholic fatty liver disease without portal hypertension or cirrhosis) and/or participants with any of the following results at screening: 1. AST ≥ 2.5 × ULN 2. ALT ≥ 2.5 × ULN 3. TBL ≥ 1.5 × ULN. 8. Prior history of cholecystectomy or untreated cholelithiasis. 9. History of acute or chronic pancreatitis or pancreatic amylase or lipase \> 2 × ULN at screening. 10. Severely uncontrolled hypertension defined as systolic BP ≥ 160 mmHg and/or diastolic BP ≥ 100 mmHg on the average of 2 seated measurements after being at rest for at least 5 minutes. 11. HR \< 50 bpm or \> 100 bpm after being at rest for 5 minutes. 12. Impaired renal function defined as eGFR ≤ 45 mL/minute/1.73 m2 at screening (GFR estimated according to CKD-EPI). 13. History of psychosis or bipolar disorder. 14. Severe vitamin D deficiency defined as a 25-OH vitamin D level \< 12 ng/mL. 15. Uncontrolled thyroid disease, defined as TSH \> ULN or \< LLN for the laboratory reference range, as judged by the PI at screening. Sub-study 2 only 16. Personal or family history (first-degree relative) of MTC or MEN2. 17. History of marijuana or THC use within 3 months before screening, or unwilling/unable to abstain from marijuana or THC use during the study. 18. Previous hospitalisation for any psychiatric reason. 19. PHQ-9 score ≥ 15 within the 2 years prior to screening or at screening.